A POTENTIALLY “game changing” drug that tackles the root causes of autism could be available in the UK within five years, experts say. Initial trial results for Balovaptan has so impressed US regulators, it has been given “accelerated status”, paving the way for faster approval.

The treatment developed by drug giant Roche acts on a brain receptor for the hormone vasopressin, which is believed to influence social bonding.

During the 12-week trial of 223 men, one group had the treatment and the other a placebo.

 

Read the full article here